STOCK TITAN

AngioDynamics to Report Fiscal 2024 First Quarter Financial Results on October 4, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
AngioDynamics, Inc. will report Q1 FY2024 financial results on October 4, 2023, before market open. Conference call scheduled at 8:00 a.m. ET to discuss results. Webcast available on company website. Recording of call available until October 11, 2023.
Positive
  • None.
Negative
  • None.

LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the first quarter of fiscal year 2024 before the market open on Wednesday, October 4, 2023. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

To participate in the conference call, dial 1-877-407-0784 (domestic) or +1- 201-689-8560 (international) and refer to the passcode 13741149.

This conference call will also be webcast and can be accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available from 11:00 a.m. ET on Wednesday, October 4, 2023, until 11:59 p.m. ET on Wednesday, October 11, 2023. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13741149.

About AngioDynamics, Inc.

AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients.

The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.

Investors:

AngioDynamics, Inc.

Stephen Trowbridge, Executive Vice President & CFO

(518) 795-1408

Source: AngioDynamics, Inc.

AngioDynamics, Inc.

NASDAQ:ANGO

ANGO Rankings

ANGO Latest News

ANGO Stock Data

268.04M
40.28M
5.42%
81.92%
3.64%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
LATHAM